LanteRNA is a start-up company on a mission to enable pharma and biotech companies to faster get their new mRNA therapeutics to the market. We do this by enabling visualization of mRNA in live cells using our proprietary and patent pending fluorescent building blocks. Our aim is, through extensive R&D, to develop new innovative technical solutions that support RNA drug discovery and research to help realize new therapeutics for the benefit of patients with unmet medical needs.

Our story

The company was founded in 2021 by Prof. Elin Esbjörner Winters and Prof. Marcus Wilhelmsson together with four scientists from their respective academic research groups at Chalmers University of Technology. The two groups have a leading position in nucleic acid label development, microscopy/spectroscopy of nucleic acids, and understanding of drug delivery processes. 

The company's patent pending technologies originate from the industrial research centre for functional RNA delivery - FoRmulaEx - where three academic partners carry out research in close cooperation with pharma/biotech companies. The aim is to contribute with fundamental knowledge required for the design of safe and efficient nanoscale drug-delivery vehicles for next generation nucleotide drugs.

In 2021 Prof. Esbjörner Winters and Prof. Wilhelmsson jointly were awarded the yearly Areas of Advance Award for their contributions to this field of research. Moreover, for the recent published methodology their research has been appointed as one of the best research project ideas for commercialization in an exclusive list compiled by the Royal Swedish Academy of Engineering Sciences.


Felix Mossberg

Marcus Wilhelmsson

Chairman & Co-founder, Professor

Jesper Nilsson

CTO & Co-founder, Ph.D

Sofi Gummeson

Senior Research Scientist, M.Sc.


Elin Esbjörner

Board member, Professor

Pauline Pfeiffer


Tom Baladi


Audrey Gallud



Ana Maria Popescu

Board member